Preliminary PK parameters of eftoza in AML in cycle 1 after monotherapy or in combination with venetoclax
| PK parameter . | 1.25 mg/kg monotherapy (n = 1)∗ . | 3.75 mg/kg monotherapy (n = 1)∗ . | 3.75 mg/kg combination (n = 10) . | 7.5 mg/kg monotherapy (n = 2)∗ . | 7.5 mg/kg combination (n = 13) . |
|---|---|---|---|---|---|
| Cmax (μg/mL) | 12.9 | 49.3 | 58.9 (62.5, 41) | 98.3, 107 | 134 (139, 27) |
| AUC0-168 (h∗μg/mL) | 352 | 1440 | 1550 (1670, 44) | 2930, 2670 | 3480 (3550, 21) |
| t1/2 (h)† | 30.4 | 31.2 | 34.1 ± 10.1 | 30.3, 20.9 | 28.6 ± 5.93 |
| PK parameter . | 1.25 mg/kg monotherapy (n = 1)∗ . | 3.75 mg/kg monotherapy (n = 1)∗ . | 3.75 mg/kg combination (n = 10) . | 7.5 mg/kg monotherapy (n = 2)∗ . | 7.5 mg/kg combination (n = 13) . |
|---|---|---|---|---|---|
| Cmax (μg/mL) | 12.9 | 49.3 | 58.9 (62.5, 41) | 98.3, 107 | 134 (139, 27) |
| AUC0-168 (h∗μg/mL) | 352 | 1440 | 1550 (1670, 44) | 2930, 2670 | 3480 (3550, 21) |
| t1/2 (h)† | 30.4 | 31.2 | 34.1 ± 10.1 | 30.3, 20.9 | 28.6 ± 5.93 |
Values showed as geometric mean (arithmetic mean, % CV).
%CV, coefficient of variation percentage; AUC, area under the concentration-time curve; Cmax, maximum plasma concentration; t1/2, terminal phase elimination half-life.
n < 3 presented as individual values.
Showed as harmonic mean ± pseudostandard deviation.